Decreased Th17 and antigen-specific humoral responses in CX 3CR1-deficient mice in the collagen-induced arthritis model

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1379-1387

  Tarrant, Teresa K ^a   Liu, Peng ^a   Rampersad, Rishi R ^a   Esserman, Denise ^a   Rothlein, Lisa R ^a   Timoshchenko, Roman G ^a   McGinnis, Marcus W ^a   Fitzhugh, David J ^a   Patel, Dhavalkumar D ^b,c   Fong, Alan M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; COLLAGEN TYPE 2; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ARTICLE; BONE EROSION; CELL PROLIFERATION; CHRONIC ARTHRITIS; CHRONIC INFLAMMATORY ARTHRITIS; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE SEVERITY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; WILD TYPE;

EID: 84860437655     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34320     Document Type: Article

References (43)

1. Tarrant TK, Patel DD,. Chemokines and leukocyte trafficking in rheumatoid arthritis. Pathophysiology 2006; 13: 1-14.
2. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, Van den Bosch F, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2387-92.
3. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008; 58: 1931-9.
4. 3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000; 20: 4106-14.
5. D'Haese JG, Demir IE, Friess H, Ceyhan GO,. Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets 2010; 14: 207-19.
6. Ruth JH, Volin MV, Haines GK III, Woodruff DC, Katschke KJ Jr, Woods JM, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001; 44: 1568-81.
7. Sawai H, Park YW, He X, Goronzy JJ, Weyand CM,. Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2007; 56: 3215-25.
8. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol 2004; 173: 7010-6.
9. Liu P, Patil S, Rojas M, Fong AM, Smyth SS, Patel DD,. CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2006; 26: 2056-62.
10. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003; 111: 1241-50.
11. Liu P, Yu YR, Spencer JA, Johnson AE, Vallanat CT, Fong AM, et al. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol 2008; 28: 243-50.
12. Kimouli M, Miyakis S, Georgakopoulos P, Neofytou E, Achimastos AD, Spandidos DA,. Polymorphisms of fractalkine receptor CX3CR1 gene in patients with symptomatic and asymptomatic carotid artery stenosis. J Atheroscler Thromb 2009; 16: 604-10.
13. Full LE, Ruisanchez C, Monaco C,. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2009; 11: 217.
14. 3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998; 273: 23799-804.
15. 3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-30.
16. Wooley PH, Luthra HS, Stuart JM, David CS,. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981; 154: 688-700.
17. Rampersad RR, Esserman D, McGinnis MW, Lee DM, Patel DD, Tarrant TK,. S100A9 is not essential for disease expression in an acute (K/BxN) or chronic (CIA) model of inflammatory arthritis. Scand J Rheumatol 2009; 38: 445-9.
18. Rampersad RR, Tarrant TK, Vallanat CT, Quintero-Matthews T, Weeks MF, Esserman DA, et al. Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS One 2011; 6: e25833.
19. Holmdahl R, Klareskog L, Andersson M, Hansen C,. High antibody response to autologous type II collagen is restricted to H-2q. Immunogenetics 1986; 24: 84-9.
20. Wooley PH, Luthra HS, Krco CJ, Stuart JM, David CS,. Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum 1984; 27: 1010-7.
21. Quinones MP, Ahuja SK, Jimenez F, Schaefer J, Garavito E, Rao A, et al. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest 2004; 113: 856-66.
22. Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4[sym]43[/sym] T cell activation in mice. Proc Natl Acad Sci U S A 2007; 104: 20878-83.
23. Kolls JK, Linden A,. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-76.
24. Diggle PJ, Heagerty P, Liang KY, Zerger SL,. Analysis of longitudinal data. 2nd ed. Oxford: Oxford University Press; 2002.
25. Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001; 44: 2750-60.
26. 3CL1 driven chemotaxis of tonsil centrocytes [published erratum appears in PLoS One 2010;5]. PLoS One 2009; 4: e8485.
27. + dendritic cells are a steady-state population related to plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2010; 107: 14745-50.
28. Van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB,. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 164-72.
29. Mima T, Nishimoto N,. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009; 21: 224-30.
30. Koenders MI, van den Berg WB,. Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin Exp Immunol 2010; 159: 131-6.
31. Mus AM, Cornelissen F, Asmawidjaja PS, van Hamburg JP, Boon L, Hendriks RW, et al. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum 2010; 62: 1043-50.
32. Rengel Y, Ospelt C, Gay S,. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007; 9: 221.
33. Jacobs JP, Ortiz-Lopez A, Campbell JJ, Gerard CJ, Mathis D, Benoist C,. Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis Rheum 2010; 62: 1921-32.
34. Pingiotti E, Cipriani P, Marrelli A, Liakouli V, Fratini S, Penco M, et al. Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28- T cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci 2007; 1107: 32-41.
35. 3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 2006; 54: 3408-16.
36. 3C motif. Nature 1997; 385: 640-4.
37. Papadopoulos EJ, Sassetti C, Saeki H, Yamada N, Kawamura T, Fitzhugh DJ, et al. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol 1999; 29: 2551-9.
38. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 2000; 164: 3368-76.
39. Brand S, Sakaguchi T, Gu X, Colgan SP, Reinecker HC,. Fractalkine-mediated signals regulate cell-survival and immune-modulatory responses in intestinal epithelial cells. Gastroenterology 2002; 122: 166-77.
40. + dendritic cells supporting inflammatory immune responses under normal and inflammatory conditions. J Immunol 2010; 184: 2026-37.
41. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, Hornung V, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004; 103: 3058-64.
42. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-40.
43. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL,. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-4.